AKT1 and melanoma: In addition, luteolin showed a potent capacity to target HIF-1α/VEGF signaling–mediated EMT and angiogenesis, as demonstrated by EMT suppression (increased E-cadherin and decreased N-cadherin and vimentin) and the downregulation of p-AKT, HIF-1α, VEGF-A, p-VEGFR-2, MMP-2, and MMP-9 in A375 and B16-F10 melanoma cells [155].